Unidad de Fases I - START Madrid

Unidad de Fases I - START Madrid

​​

FASES I – START MADRID

 

  • An open-label, multi-center, dose escalation phase I study of single agent RO5520985, administered as an intravenous infusion in patients with locally advanced or metastatic solid tumors.

 

Más información aquí

 

  • "A Phase 1/2, Open-label Study of NivolumabMonotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors"

 

Más información aquí

 

  • "A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cáncer"

 

Más información aquí

 

  • "An Open-Label, Phase 2 Study of NERATINIB in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2,HER3) Mutations of EGFR Gene Amplification"

 

Más información aquí

 

  • A Phase I dose-escalation study of NBTXR3 activated by intensity modulated radiation therapy in patient with locally advanced squamous cell carcinoma of the oral cavity or oropharynx

 

Más información aquí

 

  • "A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with estrogen receptor positive, HER2 negative locally recurrent or advanced metastatic breast cancer."

 

Más información aquí

 

  • An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment

 

Más información aquí

 

  • "A Phase Ib study of the safety and pharmacology of MPDL3280A administered with Erlotinib in patients with advanced Non-Small Cell Lung Cancer"

 

Más información aquí

 

  • "A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer"

 

Más información aquí

 

  • "A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors"

 

Más información aquí

 

  • "An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects with BRAF V600 Mutation Positive Tumors"

 

Más información aquí

 

  • "A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumors"

 

Más información aquí

 

  • "A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of MOXR0916 administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors"

    Más información aquí

 

  • "A Phase 1 Study of ABBV-221 in Subjects with Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor"

    Más información aquí

 

  • "A first-in-human Phase I, dose escalation, safety and pharmacokinetic study of PF-06647020 in adult patient with advanced solid tumors"

    Más información aquí

 

  • "A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands"

    Más información aquí

 

  • An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

    Más información aquí

 

  • "An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium"

    Más información aquí

 

  • "A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors"

    Más información aquí

     
  • "Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors"

Más información aquí

 

  • An open-label, multicenter, dose-escalation phase I study of RO6874813, administered intravenously in patients with locally advanced or metastatic solid tumors.

Más información aquí

 

  • A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies

Más información aquí

 

  • A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination with Carboplatin: Part A: Dose Escalation of Olaparib in Combination with Carboplatin in Patients with Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination with Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients with germline BRCA1/2 mutations.

Más información aquí

 

  • "A phase I, multi-center, open label, drug-drug interaction study to assess the effect of ceritinib on the pharmacokinetics of warfarin and midazolam administered as a two-drug cocktail in patients with ALK-positive advanced tumors including non-small cell lung cancer (NSCLC) "

Más información aquí

 

  • An open-label, multicenter, dose escalation phase Ib study with expansion cohorts to evaluate the safety, pharmacokinetics, pharmacodynamics and therapeutic activity of RO7009789 (cd40 agonist monoclonal antibody) in combination with Vanucizumab (anti-ang2 and anti-VEGF BI-specific monoclonal antibody) in patients with metastatic solid tumors

Más información aquí

 

  • Estudio de fase I/II, abierto, multicéntrico, de la eficacia y la seguridad de PDR001 administrado en pacientes con tumores malignos avanzados

Más información aquí

 

 

  • A Multicenter, Phase 1, Open-Label, Dose Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

Más información aquí

 

  • A phase Ib, open-label, dose-escalation study of the safety and pharmacokinetics of MOXR0916 and MPDL3280A in patient with locally advanced or metastatic solid

Más información aquí

 

  • A phase  1-2 ascending dose study to assess the pharmacodynamics, pharmakinetics, and safety of HSP-130  in subjects with non-metastatic breast cancer following single dose and multiple-dose administration by subcutaneous injection

Más información aquí

 

  • An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary anti-tumor activity, pharmacokinetics and maximum tolerated dose of BAY 1251152 in patients with advanced cancer.

Más información aquí

 

 

​ 

To Top